Basi razionali della terapia del diabete mellito tipo 2

Translated title of the contribution: Rational basis of diabetes mellitus type 2 therapy

Research output: Contribution to journalArticle

Abstract

Diabetes mellitus type 2 (T2DM) is characterized by bifactorial pathogenesis, impaired insulin secretion and increased insulin resistance; whether insulin resistance or insulin deficiency is the primary disorder have been intensively debated. Patients with T2DM are at risk of developing long term complications' including microvascular, macrovascular and neuropathic disease. The early intervention in T2DM treatment should include patient education, dietary counselling and changes in life style. Oral drug therapies include sulphonylurea derivatives, metformin (which is the treatment of choice in obese patients), combination of two classes, alfa-glucosidase inhibitors such as acarbose, used mainly to reduce post-prandial blood glucose peaks. Insulin may be required when oral hypoglycaemic drugs failed to control high blood levels. Hypertension, hyperlipidemia, coronary heart disease and obesity require particular care in diabetic patients. New drugs as alanine derivatives (repaglinide, nateglinide) and thiazolidinediones (rosiglitazone, pioglitazone) could have increasing importance in the early future.

Original languageItalian
Pages (from-to)149-154
Number of pages6
JournalOspedale Maggiore
Volume94
Issue number2
Publication statusPublished - 2000

Fingerprint

Type 2 Diabetes Mellitus
repaglinide
rosiglitazone
pioglitazone
Insulin
nateglinide
Insulin Resistance
Acarbose
Thiazolidinediones
Metformin
Patient Education
Hyperlipidemias
Hypoglycemic Agents
Alanine
Coronary Disease
Meals
Blood Glucose
Life Style
Counseling
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Basi razionali della terapia del diabete mellito tipo 2. / Pontiroli, A. E.

In: Ospedale Maggiore, Vol. 94, No. 2, 2000, p. 149-154.

Research output: Contribution to journalArticle

@article{77cb8eaee8334fada7304c99db27f88d,
title = "Basi razionali della terapia del diabete mellito tipo 2",
abstract = "Diabetes mellitus type 2 (T2DM) is characterized by bifactorial pathogenesis, impaired insulin secretion and increased insulin resistance; whether insulin resistance or insulin deficiency is the primary disorder have been intensively debated. Patients with T2DM are at risk of developing long term complications' including microvascular, macrovascular and neuropathic disease. The early intervention in T2DM treatment should include patient education, dietary counselling and changes in life style. Oral drug therapies include sulphonylurea derivatives, metformin (which is the treatment of choice in obese patients), combination of two classes, alfa-glucosidase inhibitors such as acarbose, used mainly to reduce post-prandial blood glucose peaks. Insulin may be required when oral hypoglycaemic drugs failed to control high blood levels. Hypertension, hyperlipidemia, coronary heart disease and obesity require particular care in diabetic patients. New drugs as alanine derivatives (repaglinide, nateglinide) and thiazolidinediones (rosiglitazone, pioglitazone) could have increasing importance in the early future.",
keywords = "Biguanides, Hyperglycaemia, Hyperinsulinism, Obesity, Sulphonylureas, X-Syndrome",
author = "Pontiroli, {A. E.}",
year = "2000",
language = "Italian",
volume = "94",
pages = "149--154",
journal = "Ospedale Maggiore",
issn = "0369-7843",
publisher = "Masson Italia Periodici",
number = "2",

}

TY - JOUR

T1 - Basi razionali della terapia del diabete mellito tipo 2

AU - Pontiroli, A. E.

PY - 2000

Y1 - 2000

N2 - Diabetes mellitus type 2 (T2DM) is characterized by bifactorial pathogenesis, impaired insulin secretion and increased insulin resistance; whether insulin resistance or insulin deficiency is the primary disorder have been intensively debated. Patients with T2DM are at risk of developing long term complications' including microvascular, macrovascular and neuropathic disease. The early intervention in T2DM treatment should include patient education, dietary counselling and changes in life style. Oral drug therapies include sulphonylurea derivatives, metformin (which is the treatment of choice in obese patients), combination of two classes, alfa-glucosidase inhibitors such as acarbose, used mainly to reduce post-prandial blood glucose peaks. Insulin may be required when oral hypoglycaemic drugs failed to control high blood levels. Hypertension, hyperlipidemia, coronary heart disease and obesity require particular care in diabetic patients. New drugs as alanine derivatives (repaglinide, nateglinide) and thiazolidinediones (rosiglitazone, pioglitazone) could have increasing importance in the early future.

AB - Diabetes mellitus type 2 (T2DM) is characterized by bifactorial pathogenesis, impaired insulin secretion and increased insulin resistance; whether insulin resistance or insulin deficiency is the primary disorder have been intensively debated. Patients with T2DM are at risk of developing long term complications' including microvascular, macrovascular and neuropathic disease. The early intervention in T2DM treatment should include patient education, dietary counselling and changes in life style. Oral drug therapies include sulphonylurea derivatives, metformin (which is the treatment of choice in obese patients), combination of two classes, alfa-glucosidase inhibitors such as acarbose, used mainly to reduce post-prandial blood glucose peaks. Insulin may be required when oral hypoglycaemic drugs failed to control high blood levels. Hypertension, hyperlipidemia, coronary heart disease and obesity require particular care in diabetic patients. New drugs as alanine derivatives (repaglinide, nateglinide) and thiazolidinediones (rosiglitazone, pioglitazone) could have increasing importance in the early future.

KW - Biguanides

KW - Hyperglycaemia

KW - Hyperinsulinism

KW - Obesity

KW - Sulphonylureas

KW - X-Syndrome

UR - http://www.scopus.com/inward/record.url?scp=0033831361&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033831361&partnerID=8YFLogxK

M3 - Articolo

VL - 94

SP - 149

EP - 154

JO - Ospedale Maggiore

JF - Ospedale Maggiore

SN - 0369-7843

IS - 2

ER -